Venture Capital News: Souffle Therapeutics Nets $135M Series B
2026-10-19
Tweet
BOSTON, MA, Souffle Therapeutics, a leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives, announced the close of an oversubscribed $135 million Series B financing led by Juvia Group.
Souffle Therapeutics, a leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives, announced the close of an oversubscribed $135 million Series B financing.
The round was led by Juvia Group and welcomes leading institutional investors TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a Leading Sovereign Wealth Fund, to Souffle's existing group of exceptional syndicate partners. The round was also supported by existing investors, including Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek and Vida Ventures.
The round was led by Juvia Group and welcomes leading institutional investors TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a Leading Sovereign Wealth Fund, to Souffle's existing group of exceptional syndicate partners. The round was also supported by existing investors, including Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek and Vida Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
